SARTORIUS STEDIM BIOTECH Sartorius Stedim
Biotech S.A.
Aubagne, January 5, 2022
Half-year liquidity contract statement for Sartorius Stedim Biotech
Under the liquidity contract entered into between Sartorius Stedim Biotech and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31st 2021:
- 3,361 shares
- € 9,978,179.44
- Number of executions on buy side on semester: 2,810
- Number of executions on sell side on semester: 2,600
- Traded volume on buy side on semester: 95,701 shares for € 44,247,756.63
- Traded volume on sell side on semester: 94,714 shares for € 45,073,166.52
As a reminder :
the following resources appeared on the last half year statement on 30 June 2021 on the liquidity account:
- 2,374 shares
- € 9,177,482.91
- Number of executions on buy side on semester: 659
- Number of executions on sell side on semester: 538
- Traded volume on buy side on semester: 24,109 shares for € 8,777,527.71
- Traded volume on sell side on semester: 21,735 shares for € 7,961,330.63
the following resources appeared on the liquidity account when the activity started:
- 0 shares
- € 10,000,000.00
The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted
market practice.
1 | 4
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2020, the company employed more than 7,500 people, and earned sales revenue of 1,910 million euros.
Contact
Petra Kirchhoff
Head of Corporate Communications & Investor Relations +49 (0)551.308.1686 Petra.kirchhoff@sartorius.com
Sartorius Stedim Biotech S.A.
Z.I. Les Paluds
Avenue de Jouques, CS 91051 13781 Aubagne Cedex, France Phone: +33.(0)4.42.84.56.00 Fax: +33.(0)4.42.84.56.19 www.sartorius-stedim.com
2 | 4
APPENDIX H2 2021
Buy side | Sell side | |||||
Number of | Number of | Traded volume | Number of | Number of | Traded volume | |
executions | shares | in EUR | executions | shares | in EUR | |
TOTAL | 2,810 | 95,701 | 44,247,756.63 | 2,600 | 94,714 | 45,073,166.52 |
01/07/2021 | 52 | 2,000 | 790,040.00 | 11 | 300 | 120,741.00 |
02/07/2021 | 4 | 300 | 118,200.00 | 20 | 500 | 198,220.00 |
05/07/2021 | 11 | 400 | 157,400.00 | 6 | 104 | 41,275.52 |
06/07/2021 | - | - | - | 51 | 2,096 | 859,234.24 |
07/07/2021 | - | - | - | 26 | 1,100 | 467,203.00 |
08/07/2021 | - | - | - | 9 | 400 | 175,200.00 |
09/07/2021 | 41 | 1,300 | 563,784.00 | - | - | - |
12/07/2021 | - | - | - | 45 | 1,100 | 485,100.00 |
13/07/2021 | 13 | 600 | 262,422.00 | 7 | 300 | 133,860.00 |
14/07/2021 | 1 | 51 | 22,593.00 | 4 | 300 | 134,700.00 |
16/07/2021 | - | - | - | 9 | 200 | 91,900.00 |
19/07/2021 | 42 | 1,349 | 613,646.61 | 4 | 100 | 46,250.00 |
20/07/2021 | 35 | 1,900 | 857,451.00 | - | - | - |
21/07/2021 | 143 | 5,996 | 2,620,431.88 | 32 | 1,009 | 458,802.39 |
22/07/2021 | 16 | 500 | 218,000.00 | 82 | 2,091 | 938,900.82 |
23/07/2021 | 1 | 100 | 45,600.00 | 38 | 1,175 | 542,732.50 |
26/07/2021 | 21 | 900 | 413,091.00 | 20 | 625 | 291,443.75 |
27/07/2021 | 10 | 400 | 181,772.00 | 20 | 800 | 368,400.00 |
28/07/2021 | 3 | 200 | 92,300.00 | 34 | 1,000 | 468,500.00 |
29/07/2021 | 11 | 400 | 187,400.00 | 7 | 200 | 94,700.00 |
30/07/2021 | 11 | 400 | 187,600.00 | 31 | 1,400 | 671,300.00 |
02/08/2021 | 10 | 500 | 239,500.00 | 15 | 400 | 193,400.00 |
03/08/2021 | 2 | 100 | 48,300.00 | 11 | 500 | 243,620.00 |
04/08/2021 | 6 | 100 | 48,300.00 | 14 | 500 | 246,000.00 |
05/08/2021 | - | - | - | 22 | 600 | 297,300.00 |
06/08/2021 | 52 | 1,600 | 776,800.00 | - | - | - |
09/08/2021 | - | - | - | 18 | 500 | 244,000.00 |
10/08/2021 | 1 | 100 | 49,000.00 | 30 | 856 | 423,035.20 |
11/08/2021 | 15 | 600 | 291,900.00 | - | - | - |
12/08/2021 | 18 | 701 | 336,472.99 | 4 | 144 | 69,651.36 |
13/08/2021 | 2 | 199 | 94,923.00 | - | - | - |
16/08/2021 | 14 | 200 | 95,100.00 | 5 | 300 | 144,600.00 |
17/08/2021 | - | - | - | 40 | 1,700 | 835,992.00 |
18/08/2021 | - | - | - | 26 | 1,000 | 504,500.00 |
19/08/2021 | 67 | 1,900 | 935,351.00 | 19 | 600 | 296,442.00 |
20/08/2021 | 5 | 100 | 50,000.00 | 42 | 1,500 | 755,595.00 |
23/08/2021 | - | - | - | 5 | 200 | 103,300.00 |
24/08/2021 | - | - | - | 1 | 100 | 52,000.00 |
25/08/2021 | - | - | - | 1 | 100 | 52,500.00 |
31/08/2021 | - | - | - | 4 | 100 | 53,060.00 |
20/09/2021 | 98 | 1,200 | 596,700.00 | 4 | 400 | 208,200.00 |
21/09/2021 | - | - | - | 36 | 800 | 423,384.00 |
23/09/2021 | - | - | - | 4 | 200 | 107,600.00 |
27/09/2021 | 120 | 3,500 | 1,722,770.00 | - | - | - |
28/09/2021 | 146 | 3,614 | 1,708,265.52 | - | - | - |
29/09/2021 | - | - | - | 113 | 3,200 | 1,556,512.00 |
30/09/2021 | - | - | - | 4 | 200 | 98,500.00 |
01/10/2021 | 125 | 5,000 | 2,309,750.00 | 9 | 400 | 189,200.00 |
04/10/2021 | 125 | 5,491 | 2,416,534.19 | 1 | 100 | 45,200.00 |
05/10/2021 | 7 | 100 | 43,540.00 | 82 | 3,300 | 1,479,258.00 |
06/10/2021 | 39 | 1,400 | 620,704.00 | - | - | - |
07/10/2021 | 50 | 2,200 | 968,990.00 | 44 | 851 | 380,082.13 |
08/10/2021 | 17 | 700 | 305,900.00 | 17 | 749 | 331,597.28 |
11/10/2021 | 35 | 1,000 | 429,500.00 | 6 | 300 | 129,600.00 |
12/10/2021 | 10 | 200 | 85,800.00 | 49 | 2,104 | 924,729.04 |
13/10/2021 | - | - | - | 110 | 3,596 | 1,628,700.32 |
3 | 4
Buy side | Sell side | |||||
Number of | Number of | Traded volume | Number of | Number of | Traded volume | |
executions | shares | in EUR | executions | shares | in EUR | |
14/10/2021 | 1 | 100 | 45,660.00 | 53 | 2,000 | 933,460.00 |
15/10/2021 | 10 | 400 | 186,200.00 | 37 | 600 | 283,002.00 |
18/10/2021 | 24 | 700 | 324,618.00 | 8 | 400 | 187,860.00 |
19/10/2021 | 26 | 1,200 | 560,400.00 | 35 | 1,100 | 523,699.00 |
20/10/2021 | 99 | 3,200 | 1,467,872.00 | 27 | 3,200 | 1,498,272.00 |
21/10/2021 | 1 | 100 | 46,900.00 | 36 | 2,000 | 959,000.00 |
22/10/2021 | 8 | 500 | 239,500.00 | 52 | 600 | 291,900.00 |
25/10/2021 | - | - | - | 26 | 700 | 338,338.00 |
26/10/2021 | 48 | 1,900 | 901,987.00 | 34 | 1,100 | 528,902.00 |
27/10/2021 | 60 | 2,516 | 1,189,439.00 | 10 | 600 | 288,900.00 |
28/10/2021 | 12 | 384 | 180,311.04 | 19 | 800 | 380,400.00 |
29/10/2021 | 2 | 100 | 47,100.00 | - | - | - |
01/11/2021 | - | - | - | 23 | 1,100 | 533,500.00 |
02/11/2021 | 5 | 200 | 96,300.00 | 14 | 700 | 344,400.00 |
03/11/2021 | - | - | - | 6 | 200 | 99,300.00 |
04/11/2021 | 2 | 100 | 49,300.00 | 15 | 400 | 199,800.00 |
05/11/2021 | 218 | 5,200 | 2,432,092.00 | - | - | - |
08/11/2021 | - | - | - | 38 | 2,800 | 1,318,212.00 |
09/11/2021 | 18 | 400 | 186,940.00 | 21 | 600 | 283,500.00 |
10/11/2021 | 69 | 4,000 | 1,830,200.00 | 2 | 11 | 5,071.00 |
11/11/2021 | 12 | 300 | 136,101.00 | 19 | 789 | 364,731.03 |
12/11/2021 | - | - | - | 20 | 1,000 | 470,500.00 |
15/11/2021 | 8 | 200 | 94,700.00 | 22 | 800 | 382,000.00 |
16/11/2021 | 18 | 800 | 378,200.00 | 4 | 100 | 47,800.00 |
17/11/2021 | 8 | 300 | 142,200.00 | 38 | 1,300 | 626,197.00 |
18/11/2021 | 16 | 505 | 243,697.85 | 15 | 700 | 338,898.00 |
19/11/2021 | - | - | - | 116 | 5,200 | 2,577,380.00 |
22/11/2021 | 12 | 700 | 345,499.00 | 12 | 400 | 204,600.00 |
23/11/2021 | 212 | 6,295 | 2,979,990.05 | 20 | 500 | 239,500.00 |
24/11/2021 | 29 | 1,106 | 518,183.12 | 20 | 1,200 | 567,936.00 |
25/11/2021 | - | - | - | 56 | 1,700 | 817,666.00 |
26/11/2021 | 17 | 400 | 191,100.00 | 128 | 4,305 | 2,161,239.15 |
29/11/2021 | 37 | 1,100 | 561,000.00 | 47 | 895 | 468,980.00 |
30/11/2021 | - | - | - | 83 | 3,045 | 1,609,982.85 |
01/12/2021 | 12 | 300 | 149,100.00 | - | - | - |
02/12/2021 | 79 | 2,300 | 1,124,700.00 | - | - | - |
03/12/2021 | 18 | 800 | 386,784.00 | 22 | 1,000 | 495,500.00 |
06/12/2021 | 125 | 5,194 | 2,414,015.38 | - | - | - |
07/12/2021 | - | - | - | 103 | 4,169 | 1,985,027.66 |
08/12/2021 | 2 | 100 | 47,700.00 | 48 | 1,900 | 931,304.00 |
09/12/2021 | 8 | 200 | 95,500.00 | - | - | - |
10/12/2021 | 28 | 1,300 | 614,796.00 | - | - | - |
13/12/2021 | 13 | 500 | 233,000.00 | - | - | - |
14/12/2021 | 63 | 1,600 | 728,800.00 | - | - | - |
15/12/2021 | - | - | - | 22 | 800 | 373,200.00 |
16/12/2021 | 13 | 500 | 231,500.00 | 22 | 1,000 | 477,600.00 |
17/12/2021 | 19 | 700 | 319,900.00 | - | - | - |
20/12/2021 | 31 | 600 | 272,358.00 | 19 | 604 | 284,085.36 |
21/12/2021 | 16 | 700 | 319,403.00 | 32 | 596 | 277,044.64 |
22/12/2021 | 6 | 200 | 91,500.00 | 17 | 1,000 | 465,540.00 |
23/12/2021 | 5 | 100 | 46,300.00 | 3 | 200 | 94,100.00 |
24/12/2021 | - | - | - | 3 | 100 | 47,100.00 |
27/12/2021 | - | - | - | 22 | 932 | 443,790.44 |
28/12/2021 | - | - | - | 8 | 368 | 177,607.84 |
29/12/2021 | - | - | - | 9 | 200 | 97,400.00 |
30/12/2021 | - | - | - | 19 | 700 | 343,819.00 |
31/12/2021 | 21 | 600 | 291,078.00 | 3 | 200 | 99,100.00 |
4 | 4
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Sartorius Stedim Biotech SA published this content on 05 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 January 2022 13:57:05 UTC.
